Objectives: Describe a single center experience of hemophagocytic lymphohistiocytosis in a PICU over a 10-year period, to identify clinical features that may be associated with worse outcomes, including mortality, hospital and ICU length of stay, and functional and cognitive impairments on discharge. Design: Retrospective electronic medical record review, 2007–2017. Setting: PICU located in a large urban academic quaternary care children’s hospital. Patients: All children admitted with hemophagocytic lymphohistiocytosis to our PICU from 2007 to 2017. Interventions: None. Measurements and Main Results: All patients were identified utilizing International Classification of Diseases, 9th Revision and International Classification of Diseases, 10th Revision codes. Each chart was reviewed for demographic information, hemophagocytic lymphohistiocytosis diagnostic criteria, laboratory data, Pediatric Risk of Mortality Score III, clinical features and events of ICU stay, and PICU and hospital (length of stay). Mortality at 1 year and change in Functional Status Scale from admission to discharge were recorded. There were 42 admissions with 33 unique patients. Median Pediatric Risk of Mortality score at admission was 9 (interquartile range, 7–16). Median PICU length of stay was 7 days (interquartile range, 2–21 d) and hospital length of stay was 24 days (interquartile range, 14–37 d). During their ICU stay, 56% of patients received mechanical ventilation, 43% required vasoactives, 18% required continuous renal replacement therapy, and 5% received extracorporeal life support. Clinical factors related to increased PICU length of stay included Pediatric Risk of Mortality III score (p = 0.019), maximum lactate dehydrogenase (p = 0.017), maximum total bilirubin (p = 0.042), need for mechanical ventilation (p = 0.002), vasoactive use (p = 0.02), and secondary infection (p = 0.007). The most common therapies for hemophagocytic lymphohistiocytosis included steroids (93%), etoposide (55%), and anakinra (48%). Of the 26 patients who survived to hospital discharge, 19% had newly acquired morbidities. Overall 1-year mortality was 42%. Conclusions: Hemophagocytic lymphohistiocytosis diagnosed in the PICU is a disease with high mortality. Patients who survive to discharge had relatively little morbidity, however, the mortality risk in the year following discharge continued to remain high. The authors have not disclosed any potential conflicts of interest. For information regarding this article, E-mail: drjill14@gmail.com ©2018The Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2G2OnGU
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Introduction In recent years, platelet-rich plasma (PRP) has emerged as a promising autologous biological treatment modality fo...
-
Reuters Health News from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2rI2pFX
-
The new system cuts out the practice of “over triaging calls” and uses an algorithm to suggest to dispatchers what resources are needed fr...
-
Noninvasive ventilation (NIV) is the first-line treatment of adult patients with exacerbations of cystic fibrosis (CF). High-flow nasal oxyg...
-
The new system is meant to allow people who are hard of hearing, speech-impaired or unable to talk safely on the phone to connect with emerg...
-
Objective: It was hypothesized that adding dedicated afternoon rounds for patients’ families to supplement standard family support would imp...
-
International Journal of Environmental Research... Latest Results for Sleep and BreathingIntermitt... Evolutionary Biology News -- S...
-
The American Journal of Emergency Medicine from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2iKBYYz
-
Nature Coast EMS hopes the effort will decrease the growing number of newborn deaths in the county from EMS via xlomafota13 on Inoreader h...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου